Figure 1.

TXNIP is differentially regulated by 1,25(OH)₂D₃ in cancer cells. Immunoblots showing TXNIP protein levels in cancer cells of various tissue origins—hematological (HL-60, Jurkat, U937), prostate (LNCaP, DU145, PC3), liver (HepG2, HLE, SK-HEP-1), pancreatic (AsPC-1, BxPC-3, MIA PaCa-2), breast (MDA-MB-231, MCF-7), and colorectal (HCT116, HT-29)—after treatment with 100 nM 1,25(OH)₂D₃ for 72 h. In several cell lines, e.g., Jurkat cells, TXNIP is not detected and thus no influence of 1,25(OH)₂D₃ on its expression can be observed. In cases were basal levels are detected, 1,25(OH)₂D₃ either induced, reduced, or had no clear effect on TXNIP expression, e.g., U937, MCF-7, and HT-29, respectively. “+” and “−” denote the presence or absence of the indicated molecule/treatment, respectively.